7.74
price up icon1.71%   0.13
after-market After Hours: 7.97 0.23 +2.97%
loading
Sagimet Biosciences Inc stock is traded at $7.74, with a volume of 835.70K. It is up +1.71% in the last 24 hours and up +14.50% over the past month. Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.61
Open:
$7.59
24h Volume:
835.70K
Relative Volume:
0.49
Market Cap:
$477.96M
Revenue:
$2.00M
Net Income/Loss:
$-43.51M
P/E Ratio:
-5.7697
EPS:
-1.3415
Net Cash Flow:
$-39.73M
1W Performance:
-0.64%
1M Performance:
+14.50%
6M Performance:
+41.76%
1Y Performance:
-6.18%
1-Day Range:
Value
$7.41
$7.92
1-Week Range:
Value
$7.31
$7.95
52-Week Range:
Value
$4.50
$11.41

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name
Name
Sagimet Biosciences Inc
Name
Phone
(650) 561-8600
Name
Address
155 BOVET RD., SUITE 303, SAN MATEO
Name
Employee
16
Name
Twitter
Name
Next Earnings Date
2026-08-12
Name
Latest SEC Filings
Name
SGMT's Discussions on Twitter

Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
SGMT icon
SGMT
Sagimet Biosciences Inc
7.74 477.34M 2.00M -43.51M -39.73M -1.3415
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
529.59 126.07B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
649.81 65.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
916.80 57.70B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
313.04 40.19B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
189.99 39.82B 742.00K -1.37B -1.07B -7.0731

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-26-26 Initiated Rodman & Renshaw Buy
Feb-03-26 Initiated Guggenheim Buy
Jan-28-26 Initiated Barclays Equal Weight
Aug-11-25 Initiated Wedbush Outperform
Aug-07-25 Resumed H.C. Wainwright Buy
Jul-24-25 Initiated Canaccord Genuity Buy
Dec-06-24 Initiated Oppenheimer Outperform
Nov-12-24 Initiated UBS Buy
Jun-28-24 Downgrade Goldman Buy → Neutral
May-02-24 Initiated H.C. Wainwright Buy
Mar-25-24 Initiated Leerink Partners Outperform
Aug-08-23 Initiated Goldman Buy
Aug-08-23 Initiated JMP Securities Mkt Outperform
Aug-08-23 Initiated Piper Sandler Overweight
Aug-08-23 Initiated TD Cowen Outperform
View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Added to Russell Indexes - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT) - TradingView

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences (SGMT) Joins Russell 3000 and Russell 2000 I - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet lands in Russell indexes as acne drug trial looms - Stock Titan

Jun 29, 2026
pulisher
Jun 29, 2026

Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits

Jun 28, 2026
pulisher
Jun 27, 2026

Enterprise value to EBITDA forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBITDA forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to book forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to revenue forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Sagimet Biosciences Inc (SGMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 26, 2026
pulisher
Jun 26, 2026

0O2 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

SGMT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026
pulisher
Jun 24, 2026

Sagimet Biosciences Inc (SGMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 24, 2026
pulisher
Jun 22, 2026

Sagimet Biosciences Announces Participation in Upcoming - GlobeNewswire

Jun 22, 2026
pulisher
Jun 22, 2026

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Eastern Progress

Jun 22, 2026
pulisher
Jun 22, 2026

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Jun 22, 2026
pulisher
Jun 21, 2026

Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to S&P Biotechnology Select Industry Index - marketscreener.com

Jun 21, 2026
pulisher
Jun 20, 2026

Sagimet Biosciences (SGMT) Edges Higher as Biotech Sector Gains MomentumScalping Stock Signals - dars.gov.et

Jun 20, 2026
pulisher
Jun 19, 2026

SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive ReactionDividend Growth Analysis - dars.gov.et

Jun 19, 2026
pulisher
Jun 18, 2026

SGMT News | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill

Jun 18, 2026
pulisher
Jun 18, 2026

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged - TipRanks

Jun 18, 2026
pulisher
Jun 18, 2026

Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo

Jun 18, 2026
pulisher
Jun 18, 2026

Sagimet Biosciences Inc (SGMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Sagimet Biosciences Inc (SGMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Sagimet Biosciences Inc (SGMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Sagimet Biosciences Inc (SGMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

Sagimet Biosciences Inc (SGMT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Sagimet Biosciences Inc (SGMT) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 15, 2026

Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike - Stock Titan

Jun 15, 2026
pulisher
Jun 12, 2026

Sagimet Biosciences Announces Board Changes and Director Elections - TipRanks

Jun 12, 2026
pulisher
Jun 12, 2026

Tim Walbert resigns from Sagimet's board - TradingView

Jun 12, 2026
pulisher
Jun 12, 2026

Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG - Stock Titan

Jun 12, 2026

Sagimet Biosciences Inc Stock (SGMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Sagimet Biosciences Inc Stock (SGMT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Chauche Thierry
Chief Financial Officer
Feb 10 '26
Sale
5.36
1,312
7,033
15,688
Martins Eduardo Bruno
Chief Medical Officer
Feb 10 '26
Sale
5.36
3,640
19,511
103,296
Rozek Elizabeth
Chief Legal & Admin. Officer
Feb 10 '26
Sale
5.36
2,622
14,054
190,959
Kemble George
Executive Chairman
Nov 20 '25
Sale
7.69
37,688
289,979
81,005
$111.54
price down icon 0.05%
$56.92
price down icon 1.47%
$35.39
price up icon 0.74%
ONC ONC
$309.46
price up icon 3.97%
$81.80
price up icon 2.56%
$189.99
price up icon 0.40%
Cap:     |  Volume (24h):